Consensus Conference on Hilar Cholangiocarcinoma  by Forsmark, Christopher E. et al.
EDITORIAL
Consensus Conference on Hilar Cholangiocarcinoma
Christopher E. Forsmark1, Alessandro L. Diniz2 & Andrew X. Zhu3
1University of Florida College of Medicine, Gainesville, FL, USA, 2AC Camargo Hospital, Sao Paulo, Brazil, and 3Massachusetts General Hospital Cancer
Center/Harvard Medical School, Boston, MA, USA
Corresponding author:
Christopher E. Forsmark, University of Florida College of Medicine, Gainesville, FL, USA. Tel: +1 352 273 9474. Fax: +1 352 627 9002.
E-mail: forsmce@medicine.ufl.edu
The Consensus Conference on the Multidisciplinary Manage-
ment of Hilar Cholangiocarcinoma represents a serious effort
to assess critically the current landscape and evidence for the
diagnosis and management of hilar cholangiocarcinoma
(HCCA). While the authors are in general agreement with the
consensus statements, they have also identified a few contro-
versial areas that require further investigation.
Patients with HCCA face many hurdles in receiving effective
therapy. The disease is rare, and most patients do not have any
of the specific risk factors, making screening ineffective. The
early symptoms are often non-specific, and most patients are
not resectable when jaundice develops and the ultimate diag-
nosis is made. Tumour markers (CA 19-9) are inaccurate, par-
ticularly in the setting of jaundice. Surgery remains the only
known curative therapy, but the tendency towards the early
invasion of lymphatics, blood vessels and adjacent structures
make resection complex and often unsuccessful. Nonetheless,
as this consensus statement points out, a systematic and con-
sensus-driven approach provides the best opportunity for
patients to receive the most effective care.
While many patients may have a prodrome of weight loss
and other non-specific symptoms jaundice usually leads
patients to seek medical attention. Cross-sectional imaging
reveals the presence of intrahepatic biliary dilation. Ideally, as
this consensus conference points out, a high-quality helical
multi-slice CT scan with intravenous contrast and appropri-
ately timed scans remains the best single test to identify and
stage the tumour. The accuracy of a computed tomography
(CT) scan is degraded in the presence of a biliary stent. Unfor-
tunately, in most referral centers’ experience, patients do not
receive the most effective imaging test and are stented prior to
referral. This makes subsequent staging less accurate and repre-
sents an opportunity to improve the care for these patients
during the initial evaluation. MRI with MRCP provides addi-
tional information on the extent of biliary involvement. ERCP
is of relatively low yield in these patients, with very poor rates
of diagnosis by endobiliary cytology, even with the use of addi-
tional techniques like FISH. Also, endoscopic stenting of com-
plex hilar strictures is challenging and usually involves multiple
very small caliber stents. As the consensus statement points
out, percutaneous drain placement is usually superior to endo-
scopic stenting in these patients. In many patients, EUS-guided
FNA of strictures or nodes is also a reasonable choice to obtain
a tissue diagnosis. The consensus conference makes a very
important point; pathological confirmation is not required
prior to surgical resection. It is, however, quite important that
benign causes including IgG4-related biliary strictures, benign
strictures due to Mirrizi’s syndrome, primary sclerosing
cholangitis, or previous biliary surgery are considered prior to
surgery in patients without a tissue diagnosis. If ERCP is per-
formed, the biliary cytology should be subjected to FISH analy-
sis. Endobiliary forceps biopsy and cholangioscopy-directed
biopsy should be considered if feasible, as these techniques add
to the diagnostic yield.
Initial staging of HCC is designed to identify those patients
in whom surgery is most likely to be successful. In the consen-
sus statement authors describe the essential features that must
be assessed, including the extent of the primary tumour, vascu-
lar involvement, residual liver volume and function, the pres-
ence of nodal or distant metastases, and the patient’s ability to
tolerate surgery. Of particular note from the conference, FDG-
PET is not recommended as a routine staging procedure.
A resection with negative margins is associated with better
chances of survival for patients presenting with HCCA. The
authors have emphasized the benefits of adding liver paren-
chyma and caudate lobe resection. We support that strategy in
light of the improved survival associated with the more aggres-
sive surgical approach.1 Some patients will need a multimodali-
ty strategy to achieve an adequate future liver remnant volume,
before attempting any surgical resection. This disease should
be treated in the setting of a tertiary medical centre given its
complexity. The use of portal vein embolization may add safety
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for HCCA patients when liver parenchyma hypertrophy is
required. Portal vein embolization has been shown to be a safe
and effective procedure, even in the setting of biliary stenting.2
These strategies of complex pre-operative optimization support
the assertion that this disease is best treated in experienced
referral centres.
A careful review of good quality cross-section imaging, as
well as the patient performance status, will lead to better
surgical results, with the observation that the choice for using
high-quality CT or MRI should be based on local expertise. A
routine frozen section to evaluate margins is still a matter of
debate, and should be considered in order to achieve better
quality control of the procedure as well as a potential survival
benefit.3 We believe this should be addressed in future studies.
As previously mentioned, patients are often stented before
any surgical consultation. Although the indications and meth-
ods of biliary decompression have been controversial after the
Japanese report of increased incidence of seeding associated
with percutaneous trans-hepatic cholangiogram, the experience
with endoscopic naso-biliary drainage has not been reproduced
in Western centres.4 We agree that the use of PTC remains
standard. The number of drains and location should be made
in a ‘case-by-case’ basis and discussed with the surgical team
before any attempt at biliary manipulation.
The role of liver transplantation in this disease is clear. A liver
transplant should be the procedure of choice in patients with
primary sclerosing cholangitis (PSC). The experience from
North American centres demonstrates the impact that multimo-
dality pre-transplant treatment may offer. The improved sur-
vival of patients with incidentally discovered tumours in the
setting of PSC after an induction multimodality protocol sug-
gests an opportunity for clinical investigation of multimodality
therapy for patients with de novo HCCA. For patients with
unresectable de novo HCCA, multimodality therapy followed by
liver transplantation may be a promising opportunity. Induc-
tion therapy followed by a liver transplant should be performed
under controlled protocols owing to the limitations of graft
availability and the costs of this treatment plan. As the results
from these experiences are published, we hope to see generaliz-
able, promising outcomes duplicated at multiple centres.
The authors have not included recommendations regarding
a regional lymphadenectomy. Although the therapeutic impact
of this procedure is controversial, nodal disease burden does
represent an important predictor of survival. Efforts should be
made to determine the ideal number, and location of lymph
nodes harvested. The importance of this aspect of a resection
is supported by the inclusion of nodal status in modern staging
systems.
Despite the availability of curative treatment modalities
including surgical resection and liver transplantation, most
patients with HCCA will present with recurrent, locally
advanced, or metastatic disease with a poor prognosis. While
chemotherapy and radiation have been used extensively either
alone or in combination, there is a paucity of level one evi-
dence with well-conducted clinical trials assessing the value of
these treatment modalities in well-defined clinical settings.
As outlined in the Consensus Statements, based on the
results of a phase III trial (ABC-02) with improved survival
benefits, the combination of gemcitabine and cisplatin has
become the standard therapy for patients with advanced and
metastatic HCCA.5 However, it is worth noting that even with
the combination chemotherapy, the median survival for
patients with advanced biliary tract cancers remains < 1 year,
highlighting the unmet need for more effective systemic ther-
apy. Of the 410 patients enrolled in the ABC-02 trial, only 57
patients had HCCA and the hazard ratio for this subgroup was
0.59 (0.32–1.09). Therefore, there is a need to enrich the expe-
rience of a combination chemotherapy regimen in HCCA.
While molecularly targeted therapy holds promise to improve
the outcome for patients with HCCA, there are currently no
approved targeted therapies in cholangiocarcinoma. Moreover,
recent efforts with targeted and whole exome sequencing have
identified actionable genetic signatures in intrahepatic chlan-
giocarcinoma (ICC) including mutations in the metabolic
genes isocitrate dehydrogenase (IDH) 1 and 2 and transloca-
tions involving the fibroblast growth factor receptor 2 (FGFR2)
gene.6–9 No clear, actionable genetic signatures have been iden-
tified in HCCA.
For patients who have undergone an R0 resection for HCCA,
there is no standard adjuvant therapy. However, three ongoing
randomized phase III trials are assessing the value of various
chemotherapy regimens including capecitabine, gemcitabine-
oxaliplatin and gemcitabine-cisplatin in patients undergoing
macroscopically complete surgical resection for biliary tract can-
cers including HCCA.10 The role of adjuvant chemoradiation is
being assessed in the ongoing Southwest Oncology Group 0809
study, which is a single-arm phase II trial of post-operative gem-
citabine-capecitabine based chemotherapy followed by chemora-
diation for resected cholangiocarcinoma and gall bladder
tumours. Based on the pattern of recurrence for HCCA, for mar-
gin-positive or node-positive resected HCCA, chemoradiation
or chemotherapy should be considered. In this setting, the role
of chemotherapy and the sequence of chemotherapy and chemo-
radiation remain to be defined in prospective clinical trials.
For patients who present with unresectable HCCA, either
chemotherapy with gemcitabine/cisplatin or chemoradiation
should be considered as treatment options (ref NCCN). The
role of intraluminal brachtherapy remains to be defined. For
patients who present with local recurrence with HCCA, che-
motherapy is preferred, and radiation should be considered
only in selective settings given the known toxicity risks inher-
ent to radiation delivery to the jejunal anastomosis.
In summary, while combination chemotherapy with gemcit-
abine–cisplatin is the current standard therapy for patients
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with metastatic HCCA, the role of chemoradiation or chemo-
therapy in the adjuvant setting, in patients with unresectable
or recurrent disease remains to be defined in carefully designed
prospective clinical trials.
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